You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
22 July 2025 - Neuraxpharm Group, a Spain-based specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announced on Monday the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed head...
22 July 2025 - Chinese biotechnology company DualityBio (HKEX:9606) announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-131...
21 July 2025 - Ionis Pharmaceuticals Inc (Nasdaq: IONS) on Monday announced the publication of positive Phase 3 OASISplus data in The Journal of Allergy and Clinical Immunology (JACI) In Practice, supporting its investigational therapy donidalorsen f...
21 July 2025 - Clinical-stage cancer immunotherapy company Compugen Ltd (Nasdaq: CGEN) (TASE: CGEN) on Monday announced the first patient dosing in Sub-trial 1 of MAIA-ovarian, a global adaptive platform trial evaluating COM701 as maintenance therapy...
21 July 2025 - Biopharmaceutical company Nuvalent Inc (Nasdaq: NUVL) announced on Monday that it has dosed the first patient in its global Phase 3 ALKAZAR trial, evaluating neladalkib as a first-line treatment for patients with advanced ALK-positive ...
Orion and Bayer receive EU approval for darolutamide in metastatic hormone-sensitive prostate cancer
21 July 2025 - Finnish pharmaceutical company Orion Corporation (HEL:ORNBV) and German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) on Monday announced European Commission approval for darolutamide, an oral androgen recept...
21 July 2025 - Imaging Biometrics Limited (LON: IBAI), through its US-based subsidiary Imaging Biometrics LLC, a provider of quantitative imaging and novel therapeutics for CNS malignancies, on Monday announced a soft close to its Phase 1 clinical tr...